The first trial to explore the safety and efficacy of GLP1-RAs in patients with T2DM and moderate-to-advanced CKD was the AWARD-7 (Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease) [44]. This evidence concerns the gene GCG and chronic kidney disease.